Evidence map›Paper›PMID 30967407›Full record

ArticleBMJ open2019

Off-label drug prescriptions in French general practice: a cross-sectional study.

François Drogou, Allison Netboute, Joris Giai, Xavier Dode, David Darmon, Behrouz Kassai, Laurent Letrilliart

Abstract readMulticenter Study
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

François Drogou *Univ. Lyon, Université Claude Bernard Lyon 1, Université Saint-Étienne, Collège universitaire de médecine générale, F-69008 Lyon, F-42023 Saint-Étienne, Département de médecine générale, Lyon, France.
Allison Netboute *Univ. Lyon, Université Claude Bernard Lyon 1, Université Saint-Étienne, Collège universitaire de médecine générale, F-69008 Lyon, F-42023 Saint-Étienne, Département de médecine générale, Lyon, France.
Joris GiaiService de Biostatistique, Centre Hospitalier Universitaire de Lyon, Lyon, France.
Xavier DodeDépartement de pharmacie, Centre Hospitalier Universitaire de Lyon, Lyon, France.
David DarmonDépartement d'enseignement et de recherche en Médecine Générale, Universite de Nice Faculte de Medecine, Nice, France.
Behrouz KassaiEPICIME-Centre d'Investigation Clinique, INSERM CIC201/UMR5558, Hôpital Louis Pradel, Lyon, France.
Laurent LetrilliartUniv. Lyon, Université Claude Bernard Lyon 1, Université Saint-Étienne, Collège universitaire de médecine générale, F-69008 Lyon, F-42023 Saint-Étienne, Département de médecine générale, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesOff-label drug prescribing is a public health and economic issue. The aim of this study was to describe off-label prescription in general practice in France, in terms of frequency and nature, and to identify its main determining factors.

designMulticentre cross-sectional study

settingTwenty-three training general practice offices

participantsAll the voluntary patients coming for a medical consultation or visited at home over a cumulative period of 5 days per office between November 2015 and January 2016.

methodsEleven interns, acting as observers, collected data. Two reviewers analysed the drugs prescribed by the trainers, in order to identify those prescribed off-label in terms of their indication or the age of the patient. We used a univariate, then a multivariate model, based on hierarchical mixed-effects logistic regression.

resultsAmong the 4932 drug prescriptions registered, 911 (18.5%[95% CI17.4% to 19.6%]) were off-label, of which 865 (17.6%) due to the indication of the drug and 58 (1.2%) due to the age of the patient. The prescription never mentioned the off-label use, neither was the patient informed of it, as required by the French law. With the multivariate analysis, variables contributing to off-label prescription were the number of drugs (OR=1.05 for each additional drug), the initiation of new drug therapy (OR=1.26) and the non-specific goal of the prescription (OR=1.43); the age of the patient ≤14 years (OR=1.42); the rural location of the physician's practice (OR=1.38) and the low frequency of the visits of national health insurance representatives (OR=0.93).

conclusionAlmost one out of five drugs prescribed in French general practice was off-label. It seems necessary to better train physicians in clinical pharmacology, to provide them with more effective drug prescription software, to reinforce postmarketing surveillance and to clearly define off-label use by consensus.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolCross-Sectional StudiesDrug LabelingDrug PrescriptionsFemaleFranceGeneral PracticeHumansInfantInfant, NewbornMaledrug prescriptiongeneral practiceoff-label use

Identifiers

PMID30967407
PMCPMC6500201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.